Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892931 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
A Phase 2 study of Glioblastoma Multiforme, sponsored by Myrexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT00892931 is a Phase 2 study of Glioblastoma Multiforme that has completed, run by Myrexis. The registered enrollment target is 56 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (42% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT00892931, a Phase 2 study of Glioblastoma Multiforme, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Conditions Studied
Interventions
- DRUG Azixa
Study Locations (10)
Massachusetts
- Tufts Medical Center - Boston
- Lahey Clinic - Burlington
- University of Massachusettes - Worcester
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Arizona
- Barrow Neurological Institute - Phoenix
Illinois
- Northwestern University - Chicago
New Hampshire
- Darthmouth -Hitchcock Medical Center - Lebanon
New York
- Columbia University - New York
Washington
- SCCA/University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892931
The ClinicalTrials.gov registry entry for NCT00892931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (42% lower). The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Azixa is the first listed.
NCT00892931 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00892931 about?
NCT00892931 is a clinical study titled "Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme". The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
What is the current status of trial NCT00892931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2011-09.
What conditions does trial NCT00892931 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT00892931?
The interventions under investigation include: Azixa (DRUG).
Who is sponsoring clinical trial NCT00892931?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892931 being conducted?
This trial has 10 study locations across Arizona, California, Illinois, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.